A selective HK2 degrader suppresses SW480 cancer cell growth by degrading HK2

被引:0
|
作者
Yang Liu [1 ]
Yan Liu [2 ]
Kaiyin Yang [3 ]
Zhiruo Zhang [1 ]
Wenbo Zhang [1 ]
Bingyou Yang [2 ]
Hua Li [1 ,4 ]
Lixia Chen [1 ]
机构
[1] Wuya College of Innovation, Key Laboratory of Structure-Based Drug Design & Discovery, Ministry of Education, Shenyang Pharmaceutical University
[2] Key Laboratory of Basic and Application Research of Beiyao, Ministry of Education, Heilongjiang University of Chinese Medicine
[3] Hubei Key Laboratory of Natural Medicinal Chemistry and Resource Evaluation, School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology
[4] Institute of Structural Pharmacology & TCM Chemical Biology, College of Pharmacy, Fujian University of Traditional Chinese
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Hexokinase 2(HK2) is the rate-limiting enzyme in the first step of glycolysis, catalyzing glucose to glucose-6-phosphate, and overexpressed in most cancer cells. HK2 also binds to voltage-dependent anion channel(VDAC) to stabilize the mitochondrial outer membrane, which inhibits cancer cell apoptosis.Therefore, HK2 has become a potential target for cancer treatment. Proteolysis targeting chimeras(PROTACs) are hetero-bifunctional molecules that recruit an E3 ubiquitin ligase to a given substrate protein resulting in its targeted degradation. Many potent and specific PROTACs targeting dissimilar targets have been developed. In this study, an HK2 PROTAC, 4H-5P-M, was developed and induced the degradation of HK2 relying on the ubiquitin-proteasome system. It was found that 4H-5P-M as an effective HK2 degrader induced HK2 degradation in a dose-and time-dependent manner and suppressed the growth of SW480 cells. 4H-5P-M selectively induced HK2 degradation at a lower concentration than other hexokinase isozymes. Moreover, it could suppress glycolysis and accelerate the apoptosis of cancer cells. Therefore, it provided a new insight into the development of anti-tumor drugs.
引用
下载
收藏
页码:228 / 231
页数:4
相关论文
共 50 条
  • [1] A selective HK2 degrader suppresses SW480 cancer cell growth by degrading HK2
    Liu, Yang
    Liu, Yan
    Yang, Kaiyin
    Zhang, Zhiruo
    Zhang, Wenbo
    Yang, Bingyou
    Li, Hua
    Chen, Lixia
    CHINESE CHEMICAL LETTERS, 2024, 35 (08)
  • [2] The Roles of HK2 on Tumorigenesis of Cervical Cancer
    Liu, Chunyan
    Wang, Xiuli
    Zhang, Youzhong
    TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2019, 18
  • [3] HK2 is conditionally essential for growth in human cancer cells
    Huggler, Kimberly S.
    Flickinger, Kyle M.
    Cantor, Jason R.
    CANCER RESEARCH, 2024, 84 (06)
  • [4] PSA and hK2 in the diagnosis of prostate cancer
    Alapont Alacreu, J. M.
    Navarro Rosales, S.
    Budia Alba, A.
    Espana Furio, F.
    Morera Martinez, F.
    Jimenez Cruz, J. F.
    ACTAS UROLOGICAS ESPANOLAS, 2008, 32 (06): : 575 - 588
  • [5] Unlocking the Potential of HK2 in Cancer Metabolism and Therapeutics
    Garcia, Sara N.
    Guedes, Rita C.
    Marques, M. Matilde
    CURRENT MEDICINAL CHEMISTRY, 2019, 26 (41) : 7285 - 7322
  • [6] Inhibition of glycolytic enzyme hexokinase II (HK2) suppresses lung tumor growth
    Huanan Wang
    Lei Wang
    Yingjie Zhang
    Ji Wang
    Yibin Deng
    Degui Lin
    Cancer Cell International, 16
  • [7] Variants of the hK2 protein gene (KLK2) are associated with serum hK2 levels and predict the presence of prostate cancer at biopsy
    Nam, Robert K.
    Zhang, William W.
    Klotz, Laurence H.
    Trachtenberg, John
    Jewett, Michael A. S.
    Sweet, Joan
    Toi, Ants
    Teahan, Seamus
    Venkateswaran, Vasunclara
    Sugar, Linda
    Loblaw, Andrew
    Siminovitch, Kathy
    Narod, Steven A.
    CLINICAL CANCER RESEARCH, 2006, 12 (21) : 6452 - 6458
  • [8] Inhibition of glycolytic enzyme hexokinase II (HK2) suppresses lung tumor growth
    Wang, Huanan
    Wang, Lei
    Zhang, Yingjie
    Wang, Ji
    Deng, Yibin
    Lin, Degui
    CANCER CELL INTERNATIONAL, 2016, 16
  • [9] Molecular markers (PSA, hK2, RT-PCR of PSA and hK2 mRNA): recent progress and perspectives
    Lilja, H
    RENAL, BLADDER, PROSTATE AND TESTICULAR CANCER: AN UPDATE, 2001, : 81 - 89
  • [10] Regulation of HK2 expression through alterations in CpG methylation of the HK2 promoter during progression of hepatocellular carcinoma
    Lee, Hyun Gyu
    Kim, Hyemi
    Son, Taekwon
    Jeong, Youngtae
    Kim, Seung Up
    Dong, Seung Myung
    Park, Young Nyun
    Lee, Jong Doo
    Lee, Jae Myun
    Park, Jeon Han
    ONCOTARGET, 2016, 7 (27) : 41798 - 41810